entertainment -WSS

entertainment

author：Wikipedia 2025-09-30 16:14:48 - browse：5

WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for cancer patients if it means making more money.

Genentech CEO Alexander Hardy, in an interview with STAT, explained that in the world that existed prior to the Inflation Reduction Act’s passage last year, drugmakers were incentivized to get drugs on the market as fast as possible, regardless of which disease they would be approved to treat.

Now, he’s arguing that the law’s new Medicare negotiation program could encourage Genentech to slow-walk research on how a drug could treat diseases with smaller populations in favor of making sure diseases with larger patient populations are the first to market. That would mean the company would sell more medicines in the window before Medicare is allowed to negotiate prices, because the clock for when discounts can kick in is based off of when the drug first goes on the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： AstraZeneca loses challenge to Medicare drug price negotiation

focus

WSS

Kenai launches with $82 million for Parkinson’s stem cell therapy

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Flu vaccine offering decent levels of protection this winter, new data show

RaDonda Vaught to speak at CommonSpirit event on patient safety

Why getting cancer drugs just got harder for rural patients

hotspot

entertainment

explore

Medical leaders decry Supreme Court decision on affirmative action

Addiction doctors spar with methadone clinics over legislation

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Biotech companies concerned about China biosecurity crackdown

Alkermes shareholders re

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Bright Health sells Medicare Advantage business to Molina

FogPharma raises $145 million in rare Series E round

Affirmative action in medical school literally saved lives

Akili, maker of video game for ADHD, to be acquired for 34 million

entertainment

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Prosthetic arm enables patients to feel the objects they grip

Addiction doctors spar with methadone clinics over legislation

FDA does about

What will save rural psychiatry services? Higher Medicaid payments

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

entertainment

hotspot

focus

hotspot